• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Lilly Modifies Purchase Agreement with U.S. for COVID Therapies

    Sanofi Acquires Tidal Therapeutics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lonza Expands PyroTec PRO for Endotoxin Testing

    FDA Accepts Airway Therapeutics’ IND for COVID Treatment

    Sanofi Invests in Cutting Edge Vax Production Site in Singapore

    Digitalization and the Future of Formulating in Modern R&D Labs

    Sanofi Acquires Tidal Therapeutics
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Syngene

    Quotient Sciences

    Adare Pharma Solutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Vaccines and Return-To-Normalcy

    Planning for a future in which COVID-19 won’t simply ‘disappear.’

    Vaccines and Return-To-Normalcy
    Ben Locwin, Contributing Editor03.01.21
    While the world was questioning if people would not be immune to COVID-19 after having recovered from COVID-19, and panicking about whether or not doors and walls were being cleaned fastidiously enough, I was determined to make public health groups aware that the only way we would REALLY be able to get out of the pandemic was by vaccination of the population (and/or acquired immunity).

    Virologically and immunologically, nobody with any real knowledge thought seriously from the outset that recovered patients wouldn’t be immune, but the scaremongering media made it their collective mission to grab on to the latest non-scientific soundbite or headline in order to sell more papers (or ad revenue slots). It’s a continuation across a different medium of the moniker, “If it bleeds, it leads,” which refers to news stories involving trauma or bloodshed getting ‘more eyes,’ in the parlance of the journalism industry.

    While I write this article, we have (in the U.S.) two authorized mRNA vaccines, and J&J (via Janssen) will be seeking EUA (Emergency Use Authorization) at the end of this month (February). So, by the time you read this column, the die will have been cast, and their AD.COV.26 vaccine, based on an adenoviral-26 vector, will either have been authorized or not.

    I had previously predicted for other media outlets the very week of J&J’s filing for EUA (as well as the outcomes for Moderna and Pfizer/BioNTech), so I’m going to prognosticate here that Janssen’s vaccine candidate will get the greenlight from the Vaccines and Related Biological Products (VRBP) Advisory Committee to recommend to the FDA for an EUA. This will give us 3 major shots (literally and figuratively) in the fight against SARS-CoV-2. But as the former Surgeon General of the United States, C. Everett Koop once said, “drugs only work in people who take them.” That’s also true of vaccines. Unless there is broad uptake globally (not just nationally!), we won’t get ahead of the vectors to sufficiently reduce R0 to make it disappear.

    But the footnote on this part of the story, as hedged now by this author, for the backward-looking lens of the future thinking back to this point and how well-prepared and accurate we were in our assessments and theories: A betacoronavirus like SARS-CoV-2 (perhaps a distant mutation) will more than likely continue circulating indefinitely now, and perhaps it becomes something for which we develop a routine booster shot (like influenza). In my estimation, we won’t be rid of this pathogen (or a derivative) anytime soon, because its mutations make it very comfortable persisting among humanity very insidiously, and sometimes even innocuously.

    We’re currently tracking variants, which include B.1.1.7, B.1.351, 501.Y2, P.1, and P.2. There are of course countless others, but the ones which concern me and others in the virology and vaccinology world are those which yield many of their specific mutations on the spike (S) glycoprotein. This part of the whole virus is really the entirety of the business end. It is how this virus attaches and gains access to cells in the body. It’s also how the body is recognizing parts of the virus in order for immunity to prevent future cases. If the new variants look ‘different enough,’ they will evade antibodies and cause the mounting of novel immune responses (and catalyze the development of new vaccines and treatments).

    In my estimation, looking at SIR epidemiological curves and population response makes me realize that COVID-19 won’t simply disappear. So, we need to proactively plan for when we deem it appropriate to stand-down on the nomenclature of global “pandemic” to allow the population to effectively get back to municipal planning and execution for a future wherein we live alongside mutating betacoronaviruses. We can’t keep the curtain closed forever. Nor can we open it without first coming up with a plan for how we do so.


    Ben Locwin
    Contributing Editor

    Dr. Ben Locwin, a health care executive, has worked on vaccinology and virology advisory boards, and has been on the front lines of the national coronavirus pandemic, participating in public health policy groups, and providing recommendations for government and private sector response amid its continued impact to public health and world economies. He has also worked closely with the FDA and the CDC.
    Related Searches
    • Biologics, Proteins, Vaccines

    Related Columns

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      What Will Change at FDA for 2021?

      What Will Change at FDA for 2021?

      (R)evolution of the industry’s data, catalyzed by changes at FDA and what’s the likely impact to the pharmaceutical industry?
      Ben Locwin, Contributing Editor, International COVID-19 Advisor, Healthcare Futurist 04.01.21

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20


    • Biologics, Proteins, Vaccines
      Outsourcing in China: How far can it go?

      Outsourcing in China: How far can it go?

      China’s biopharmaceutical services market is on pace to top $1 billion by 2021
      Vicky Qing Xia, BioPlan Associates 07.15.19

    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19

    • Biologics, Proteins, Vaccines
      Innovate UK Grant Supports Viral Vector Manufacturing

      Innovate UK Grant Supports Viral Vector Manufacturing

      Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment
      Betsy Louda, Associate Editor 04.10.18


    • Biologics, Proteins, Vaccines | Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17

    • Biologics, Proteins, Vaccines
      India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17


    • Biologics, Proteins, Vaccines
      Trends in New Technologies & Budgets

      Trends in New Technologies & Budgets

      Budget increases in biopharmaceutical industry indicate future growth
      Eric S. Langer, BioPlan Associates 06.06.17

    • Biologics, Proteins, Vaccines

      Biomanufacturing Trends and Outlook 2017: Where Is It All Going?

      A look at the technological advances permeating (bio)pharma manufacturing
      Ben Locwin, Contributing Editor 04.20.17

    • Biologics, Proteins, Vaccines
      CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges

      CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

      Technically trained staff needed to run complex manufacturing platforms, automation
      Eric S. Langer, BioPlan Associates 03.07.17


    • Biologics, Proteins, Vaccines

      Year-End Trends in Biopharma Contract Manufacturing

      Budgets are flattening, but some CMOs are well positioned for growth
      Eric S. Langer, BioPlan Associates 11.09.16

    • Biologics, Proteins, Vaccines

      Economics of In-House Buffer Preparation

      Evaluating the cost effectiveness of keeping basic ops in-house
      Eric S. Langer, BioPlan Associates 09.08.16

    • Biologics, Proteins, Vaccines | cGMP Manufacture | GMPs/GCPs | Preclinical Outsourcing | Process Development | Risk Management

      Getting to Yes

      The critical attributes CMOs need to demonstrate to win business
      Eric S. Langer, BioPlan Associates 07.14.15

    Trending
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • ANI Acquires Branded Products Portfolio From Sandoz
    • FDA Accepts Airway Therapeutics’ IND For COVID Treatment
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    Breaking News
    • Lonza Expands PyroTec PRO for Endotoxin Testing
    • FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    • Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    • Lilly Modifies Purchase Agreement with U.S. for COVID Therapies
    • Sanofi Acquires Tidal Therapeutics
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    KD Pharma Acquires Rohner AG Manufacturing Assets
    Thorne Healthtech and PreCon Health to Launch Supplements for Pre-, Post-Impact Brain Health
    Green Leafy Vegetable Intervention Reduces Marker of Colorectal Cancer Risk, Study Finds
    Coatings World

    Latest Breaking News From Coatings World

    BCF's Tom Bowtell Voted VP of World Coatings Council
    Chromaflo Technologies to Sponsor, Exhibit at North American Pultrusion Conference 2021
    EU Innovation Fund Evaluating Perstorp-created Project AIR
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Avantor to Acquire Ritter GmbH and Affiliates for $1B
    ZOLL Buys Sleep Apnea Device Maker Respicardia
    Digital Diabetes Management Market Projected to Reach $54 Billion by 2027
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Lonza Expands PyroTec PRO for Endotoxin Testing
    FDA Accepts Airway Therapeutics’ IND for COVID Treatment
    Sanofi Invests in Cutting Edge Vax Production Site in Singapore
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Honest Co. Files for an Initial Public Offering
    China Builds ‘Beauty and Healthcare Industrial Park’ in Guangzhou
    Edition Spéciale by Luxe Pack is Postponed
    Happi

    Latest Breaking News From Happi

    OTC Pain Relief QR Cream Debuts in US Market
    Professional Beauty Association Opens Registration for Summit
    Makeup Leader Laura Geller Teams Up with Actress Fran Drescher
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mark Andy launches monochrome digital print bar
    Label Traxx launches Siteline online artwork approvals system
    Kocher + Beck appoints new regional sales manager
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    NXTNano Adding Three Lines
    Honest Company Plans IPO
    Asia Wipes Summit Held Successfully in Shanghai
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    SynerFuse, Cirtec Medical Partner to Develop Back Pain Management Device
    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    NREL: 10 Teams Emerge Victorious in Round 4 of American-Made Solar Prize
    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login